Cargando…

Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases

In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetic...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Calle-Fabregat, Carlos, Rodríguez-Ubreva, Javier, Cañete, Juan D., Ballestar, Esteban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895872/
https://www.ncbi.nlm.nih.gov/pubmed/36788968
http://dx.doi.org/10.2478/rir-2022-0018
_version_ 1784881939995426816
author de la Calle-Fabregat, Carlos
Rodríguez-Ubreva, Javier
Cañete, Juan D.
Ballestar, Esteban
author_facet de la Calle-Fabregat, Carlos
Rodríguez-Ubreva, Javier
Cañete, Juan D.
Ballestar, Esteban
author_sort de la Calle-Fabregat, Carlos
collection PubMed
description In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics.
format Online
Article
Text
id pubmed-9895872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-98958722023-02-13 Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases de la Calle-Fabregat, Carlos Rodríguez-Ubreva, Javier Cañete, Juan D. Ballestar, Esteban Rheumatol Immunol Res Review In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics. Sciendo 2022-10-20 /pmc/articles/PMC9895872/ /pubmed/36788968 http://dx.doi.org/10.2478/rir-2022-0018 Text en © 2022 Carlos de la Calle-Fabregat et al., published by Sciendo https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Review
de la Calle-Fabregat, Carlos
Rodríguez-Ubreva, Javier
Cañete, Juan D.
Ballestar, Esteban
Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title_full Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title_fullStr Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title_full_unstemmed Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title_short Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases
title_sort designing studies for epigenetic biomarker development in autoimmune rheumatic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895872/
https://www.ncbi.nlm.nih.gov/pubmed/36788968
http://dx.doi.org/10.2478/rir-2022-0018
work_keys_str_mv AT delacallefabregatcarlos designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases
AT rodriguezubrevajavier designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases
AT canetejuand designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases
AT ballestaresteban designingstudiesforepigeneticbiomarkerdevelopmentinautoimmunerheumaticdiseases